Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/98113
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups
Author: Sorich, M.
Coory, M.
Pekarsky, B.
Citation: PLoS One, 2013; 8(8):e72256-1-e72256-6
Publisher: Public Library of Science
Issue Date: 2013
ISSN: 1932-6203
1932-6203
Statement of
Responsibility: 
Michael J. Sorich, Michael Coory, Brita A. K. Pekarsky
Abstract: Evidence of clinical utility is a key issue in translating pharmacogenomics into clinical practice. Appropriately designed randomized controlled trials generally provide the most robust evidence of the clinical utility, but often only data from a pharmacogenomic association study are available. This paper details a method for reframing the results of pharmacogenomic association studies in terms of the comparative treatment effect for a pharmacogenomic subgroup to provide greater insight into the likely clinical utility of a pharmacogenomic marker, its' likely cost effectiveness, and the value of undertaking the further (often expensive) research required for translation into clinical practice. The method is based on the law of total probability, which relates marginal and conditional probability. It takes as inputs: the prevalence of the pharmacogenomic marker in the patient group of interest, prognostic effect of the pharmacogenomic marker based on observational association studies, and the unstratified comparative treatment effect based on one or more conventional randomized controlled trials. The critical assumption is that of exchangeability across the included studies. The method is demonstrated using a case study of cytochrome P450 (CYP) 2C19 genotype and the anti-platelet agent clopidogrel. Indirect subgroup analysis provided insight into relationship between the clinical utility of genotyping CYP2C19 and the risk ratio of cardiovascular outcomes between CYP2C19 genotypes for individuals using clopidogrel. In this case study the indirect and direct estimates of the treatment effect for the cytochrome P450 2C19 subgroups were similar. In general, however, indirect estimates are likely to have substantially greater risk of bias than an equivalent direct estimate.
Keywords: Humans; Cardiovascular Diseases; Ticlopidine; Aryl Hydrocarbon Hydroxylases; Platelet Aggregation Inhibitors; Treatment Outcome; Models, Statistical; Pharmacogenetics; Alleles; Cost-Benefit Analysis; Randomized Controlled Trials as Topic; Genetic Association Studies
Rights: © 2013 Sorich et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
RMID: 0030043211
DOI: 10.1371/journal.pone.0072256
Grant ID: http://purl.org/au-research/grants/nhmrc/1028492
Appears in Collections:Public Health publications

Files in This Item:
File Description SizeFormat 
hdl_98113.pdfPublished version373.51 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.